Methods of modulating immunity
The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.
1. A method of treating a disease in a subject, wherein the disease is selected from the group consisting of multiple sclerosis, diabetes, graft-versus-host disease, rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus, or uveitis, the method comprising administering to the subject a dose of about 1 μg/kg to about 500 μg/kg of an anti-CD3 antibody, or an antigen-binding fragment thereof selected from the group consisting of an F(ab′)2 antibody fragment or a CD3-binding dimeric or multimeric scFv, wherein the administering is an oral dosage for ingestion.
2. The method of claim 1 , wherein the disease is diabetes.
3. The method of claim 1 , wherein the disease is rheumatoid arthritis.
4. The method of claim 1 , wherein the disease is multiple sclerosis.
5. The method of claim 1 , wherein the antigen-binding fragment is an F(ab′)2.
6. The method of claim 1 , wherein the disease is lupus.
7. The method of claim 1 , wherein the anti-CD3 antibody or antigen-binding fragment thereof is recombinant.
8. The method of claim 1 , wherein the anti-CD3 antibody or antigen-binding fragment thereof is humanized.
9. A method of providing an anti-CD3 antibody, or an antigen-binding fragment thereof selected from the group consisting of an F(ab′)2 antibody fragment or a CD3-binding dimeric or multimer scFv, to a subject having a disease selected from the group consisting of multiple sclerosis, diabetes, graft-versus-host disease, rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus, or uveitis, the method comprising administering to the subject an oral dosage form for ingestion suitable to deliver a dosage of about 1 μg/kg to about 500 μg/kg of the anti-CD3 antibody or antigen-binding fragment thereof.
10. The method of claim 1 , wherein the anti-CD3 antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody.
11. The method of claim 9 , wherein the anti-CD3 antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody.
12. The method of claim 2 , wherein the disease is type 1 diabetes.
13. The method of claim 1 , wherein the disease is graft-versus-host disease.
14. The method of claim 1 , wherein the disease is uveitis.
15. The method of claim 1 , wherein the disease is psoriasis.
16. The method of claim 1 , wherein the disease is inflammatory bowel disease.